Related Experiment Video
Updated: Jun 14, 2026

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
[Lysosomal storage diseases - update and new therapeutic options]
K Schöpfer1, E Miebach, M Beck
1Augenklinik und Poliklinik, Universitätsmedizin Mainz. schoepfer@augen.klinik.uni-mainz.de
Abstract:
Lysosomal storage diseases represent a group of about 50 genetic disorders. The deficiencies of lysosomal and non-lysosomal proteins cause an accumulation of compounds which are normally degraded within the lysosome. There are currently no therapeutic options to cure patients suffering from a lysosomal storage disease. Due to their progressive nature there is considerable morbidity and mortality. Thus, an early treatment to maintain major systemic functions is of utmost importance. While so far only symptomatic therapies are in use, the newly available enzyme replacement therapies offer a real causal approach for selected storage diseases. Many of these disorders are characterised by pathognomonic eye findings. Therefore, the ophthalmological examination provides the opportunity for an early and non-invasive diagnosis and a chance to initiate early treatment. This review is intended to give a survey of the most common lysosomal storage diseases, particularly with regard to ophthalmological changes as well as illustrate new therapeutic options.
More Related Videos
Related Concept Videos
Lysosomal Hydrolases
Pharmacogenomics: Identification of New Drug Targets
Microorganisms in Medicine and Therapeutics
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Parkinson's Disease: Overview

